

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

Fingolimod for treating relapsing multiple sclerosis in children and young people ID1378

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Novartis (fingolimod) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Brain and Spine Foundation • Disability Rights UK • Leonard Cheshire Disability • MS-UK • Multiple Sclerosis National Therapy Centres • Multiple Sclerosis Society • Multiple Sclerosis Trust • Muslim Council of Britain • Neurological Alliance • Shift.ms • South Asian Health Foundation • Specialised Healthcare Alliance • Sue Ryder • The Brain Charity <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of British Neurologists • Association of Neuroscience Nurses • British Neuropathological Society • British Society of Rehabilitation Medicine • Chartered Society of Physiotherapy • College of Occupational Therapists • Institute of Neurology • Primary Care Neurology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutic and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • Multiple Sclerosis Society Wales • National Association of Primary Care • National Pharmacy Association • Neurological Alliance of Scotland • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Wales Neurological Alliance • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Bayer (interferon beta 1b) • Biogen Idec (interferon beta 1a, natalizumab, peginterferon beta 1a) • Merck Serono (interferon beta 1a) • Mylan (glatiramer acetate) • Novartis (interferon beta 1b) • Teva (glatiramer acetate) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Brain Research Trust

Provisional matrix for the proposed technology appraisal of fingolimod for treating relapsing multiple sclerosis in children and young people ID1378. Issue date: March 2018.

Appendix C

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal Pharmaceutical Society • Royal Society of Medicine • Therapists in MS • UK Health Forum • UK Clinical Pharmacy Association • UK Multiple Sclerosis Specialist Nurse Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS Nottingham West CCG • NHS Tameside and Glossop CCG • Welsh Government 	<ul style="list-style-type: none"> • British Neurological Research Trust • Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group • MRC Clinical Trials Unit • National Hospital for Neurology and Neurosurgery • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland;; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.